Renal Congestion in Heart Failure: Insights in Novel Diagnostic Modalities.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Heart failure is increasingly prevalent and is estimated to increase its burden in the following years. A well-reported comorbidity of heart failure is renal dysfunction, where predominantly changes in the patient's volume status, tubular necrosis or other mechanical and neurohormonal mechanisms seem to drive this impairment. Currently, there are established biomarkers evaluating the patient's clinical status solely regarding the cardiovascular or renal system. However, as the coexistence of heart and renal failure is common and related to increased mortality and hospitalization for heart failure, it is of major importance to establish novel diagnostic techniques, which could identify patients with or at risk for cardiorenal syndrome and assist in selecting the appropriate management for these patients. Such techniques include biomarkers and imaging. In regards to biomarkers, several peptides and miRNAs indicative of renal or tubular dysfunction seem to properly identify patients with cardiorenal syndrome early on in the course of the disease, while changes in their serum levels can also be helpful in identifying response to diuretic treatment. Current and novel imaging techniques can also identify heart failure patients with early renal insufficiency and assess the volume status and the effect of treatment of each patient. Furthermore, by assessing the renal morphology, these techniques could also help identify those at risk of kidney impairment. This review aims to present all relevant clinical and trial data available in order to provide an up-to-date summary of the modalities available to properly assess cardiorenal syndrome.
Identifiants
pubmed: 38427026
doi: 10.1097/CRD.0000000000000673
pii: 00045415-990000000-00224
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflicts of interest to report.
Références
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171.
Gupta A, Fonarow GC. The Hospital Readmissions Reduction Program-learning from failure of a healthcare policy. Eur J Heart Fail. 2018;20:1169–1174.
Ambrosy AP, Vaduganathan M, Huffman MD, et al.; EVEREST trial investigators. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012;14:302–311.
Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure. Eur Heart J. 2012;33:2135–2142.
Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10:165–169.
Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121:2592–2600.
Brankovic M, Akkerhuis KM, Hoorn EJ, et al. Renal tubular damage and worsening renal function in chronic heart failure: clinical determinants and relation to prognosis (Bio-SHiFT study). Clin Cardiol. 2020;43:630–638.
Helal I, Fick-Brosnahan GM, Reed-Gitomer B, et al. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8:293–300.
Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13:599–608.
Owan TE, Hodge DO, Herges RM, et al. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail. 2006;12:257–262.
Verdiani V, Lastrucci V, Nozzoli C. Worsening renal function in patients hospitalized with acute heart failure: risk factors and prognostic significances. Int J Nephrol. 2010;2011:785974.
Kingma JG, Simard D, Rouleau JR, et al. The physiopathology of cardiorenal syndrome: a review of the potential contributions of inflammation. J Cardiovasc Dev Dis. 2017;4:21.
Tuttolomondo A, di Raimondo D, Pecoraro R, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18:4266–4288.
Damman K, Jaarsma T, Voors AA, et al.; COACH investigators. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail. 2009;11:847–854.
Damman K, Valente MAE, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455–469.
Damman K, Navis G, Smilde TDJ, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9:872–878.
Smilde TDJ, Damman K, van der Harst P, et al. Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure. Clin Res Cardiol. 2009;98:121–129.
Núñez J, Miñana G, Santas E, et al. Cardiorenal syndrome in acute heart failure: revisiting paradigms. Rev Esp Cardiol (Engl Ed). 2015;68:426–435.
Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–596.
Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582–588.
Tsuruya K, Eriguchi M. Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens. 2015;24:154–162.
Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32:2705–2712.
Tamayo-Gutierrez A, Ibrahim HN. The kidney in heart failure: the role of venous congestion. Methodist Debakey Cardiovasc J. 2022;18:4–10.
Zymliński R, Biegus J, Ponikowski P. Not all fluid overloads are the same: some practical considerations for better decongestion. Eur J Heart Fail. 2021;23:1106–1109.
Boorsma EM, ter Maaten JM, Voors AA, et al. Renal compression in heart failure: the renal tamponade hypothesis. JACC Heart Fail. 2022;10:175–183.
Leuning DG, Engelse MA, Lievers E, et al. The human kidney capsule contains a functionally distinct mesenchymal stromal cell population. PLoS One. 2017;12:e0187118.
Verbrugge FH, Dupont M, Steels P, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol. 2013;62:485–495.
Kitani T, Kidokoro K, Nakata T, et al. Kidney vascular congestion exacerbates acute kidney injury in mice. Kidney Int. 2022;101:551–562.
Angelini A, Castellani C, Virzì GM, et al. The role of congestion in cardiorenal syndrome type 2: new pathophysiological insights into an experimental model of heart failure. Cardiorenal Med. 2015;6:61–72.
Aboryag NB, Mohamed DM, Dehe L, et al. Histopathological changes in the kidney following congestive heart failure by volume overload in rats. Oxid Med Cell Longev. 2017;2017:6894040.
Husain-Syed F, Gröne HJ, Assmus B, et al. Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. ESC Heart Fail. 2021;8:183–203.
Terashita M, Taki Y, Sumi H, et al. Albuminuria and renal pathology in right heart failure: congestive kidney? Kidney Int Rep. 2022;7:656–657.
Koratala A, Kazory A. Natriuretic peptides as biomarkers for congestive states: the cardiorenal divergence. Dis Markers. 2017;2017:1454986.
Francis GS, Felker GM, Tang WHW. A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol. 2016;67:330–337.
Omar HR, Guglin M. Clinical and prognostic significance of positive hepatojugular reflux on discharge in acute heart failure: insights from the ESCAPE trial. Biomed Res Int. 2017;2017:5734749.
Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007;12:23–36.
Zdanowicz A, Urban S, Ponikowska B, et al. Novel biomarkers of renal dysfunction and congestion in heart failure. J Pers Med. 2022;12:898.
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–886.
Testani JM, Damman K, Brisco MA, et al. A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure. J Card Fail. 2014;20:912–919.
Collins SP, Hart KW, Lindsell CJ, et al. Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail. 2012;14:1020–1029.
Vanmassenhove J, Vanholder R, Nagler E, et al. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant. 2013;28:254–273.
Fassett RG, Venuthurupalli SK, Gobe GC, et al. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80:806–821.
Huang Z, Zhong J, Ling Y, et al. Diagnostic value of novel biomarkers for heart failure: a meta-analysis. Herz. 2020;45:65–78.
Stienen S, Salah K, Moons AH, et al. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). Circulation. 2018;137:1671–1683.
Miller WL. Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed. Circ Heart Fail. 2016;9:e002922.
Nakada Y, Kawakami R, Matsui M, et al. Prognostic value of urinary neutrophil gelatinase-associated lipocalin on the first day of admission for adverse events in patients with acute decompensated heart failure. J Am Heart Assoc. 2017;6:e004582.
Phan Thai H, Hoang Bui B, Hoang Anh T, et al. Value of plasma NGAL and creatinine on first day of admission in the diagnosis of cardiorenal syndrome type 1. Cardiol Res Pract. 2020;2020:2789410.
Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16:49–54.
Palazzuoli A, Ruocco G, Beltrami M, et al. Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. Acute Card Care. 2014;16:93–101.
Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011;13:846–851.
Lábr K, Špinar J, Pařenica J, et al. Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase-associated lipocalin. Kidney Blood Press Res. 2018;43:1865–1877.
Shlipak MG, Matsushita K, Ärnlöv J, et al.; CKD Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932–943.
de Vecchis R, Esposito C, Ariano C. Efficacy and safety assessment of isolated ultrafiltration compared to intravenous diuretics for acutely decompensated heart failure: a systematic review with meta-analysis. Minerva Cardioangiol. 2014;62:131–146.
Roos JF, Doust J, Tett SE, et al. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis. Clin Biochem. 2007;40:383–391.
Nakai K, Kikuchi M, Fujimoto K, et al. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol. 2008;12:132–139.
Fricker M, Wiesli P, Brändle M, et al. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63:1944–1947.
Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–1421.
Inker LA, Schmid CH, Tighiouart H, et al.; CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–29.
Cheang I, Liao S, Yao W, et al. Cystatin C-based CKD-EPI estimated glomerular filtration rate equations as a better strategy for mortality stratification in acute heart failure: a STROBE-compliant prospective observational study. Medicine (Baltimore). 2020;99:e22996.
Jang SY, Yang DH, Kim HJ, et al. Prognostic value of cystatin C-derived estimated glomerular filtration rate in patients with acute heart failure. Cardiorenal Med. 2020;10:232–242.
Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–2060.
Sarnak MJ, Katz R, Stehman-Breen CO, et al.; Cardiovascular Health Study. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142:497–505.
Verbree-Willemsen L, Zhang Y-N, Ibrahim I, et al. Extracellular vesicle Cystatin C and CD14 are associated with both renal dysfunction and heart failure. ESC Heart Fail. 2020;7:2240–2249.
Wu X, Xu G, Zhang S. Association between cystatin C and cardiac function and long-term prognosis in patients with chronic heart failure. Med Sci Monit. 2020;26:e919422.
Coca SG, Nadkarni GN, Huang Y, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol. 2017;28:2786–2793.
Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol. 2014;25:2177–2186.
Lin Q, Chen Y, Lv J, et al. Kidney injury molecule-1 expression in IgA nephropathy and its correlation with hypoxia and tubulointerstitial inflammation. Am J Physiol Renal Physiol. 2014;306:F885–F895.
Henry A, Gordillo-Marañón M, Finan C, et al.; HERMES and SCALLOP Consortia. Therapeutic targets for heart failure identified using proteomics and Mendelian randomization. Circulation. 2022;145:1205–1217.
Miao J, Friedman E, Wu AHB, et al. Clinical utility of single molecule counting technology for quantification of KIM-1 in patients with heart failure and chronic kidney disease. Clin Biochem. 2017;50:889–895.
Damman K, van Veldhuisen DJ, Navis G, et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010;96:1297–1302.
Emmens JE, ter Maaten JM, Matsue Y, et al. Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. Eur J Heart Fail. 2016;18:641–649.
Miñana G, Núñez J, Sanchis J, et al. CA125 and immunoinflammatory activity in acute heart failure. Int J Cardiol. 2010;145:547–548.
D’Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003;41:1805–1811.
Lourenço P, Cunha FM, Elias C, et al. CA-125 variation in acute heart failure: a single-centre analysis. ESC Heart Fail. 2022;9:1018–1026.
Núñez J, Llàcer P, Bertomeu-González V, et al.; CHANCE-HF Investigators. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: a randomized study. JACC Heart Fail. 2016;4:833–843.
Núñez J, Llàcer P, García-Blas S, et al. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am J Med. 2020;133:370–380.e4.
Núñez J, Llàcer P, Núñez E, et al. Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart failure. Int J Cardiol. 2014;174:516–523.
Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561–568.
Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197–207.
Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408.
Kestenbaum B, Sachs MC, Hoofnagle AN, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail. 2014;7:409–417.
Ix JH, Katz R, Kestenbaum BR, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012;60:200–207.
Udell JA, Morrow DA, Jarolim P, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014;63:2421–2428.
Ix JH, Shlipak MG, Wassel CL, et al. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010;25:993–997.
Marthi A, Donovan K, Haynes R, et al. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J Am Soc Nephrol. 2018;29:2015–2027.
ter Maaten JM, Voors AA, Damman K, et al. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiol. 2018;253:84–90.
Voors AA, Kremer D, Geven C, et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail. 2019;21:163–171.
Bernardo BC, Nguyen SS, Winbanks CE, et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J. 2014;28:5097–5110.
Bruno N, ter Maaten JM, Ovchinnikova ES, et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol. 2016;203:564–569.
Liu J, Zhang H, Li X, et al. Diagnostic and prognostic significance of aberrant miR-652-3p levels in patients with acute decompensated heart failure and acute kidney injury. J Int Med Res. 2020;48:300060520967829.
Lee HF, Hsu LA, Chang CJ, et al. Prognostic significance of dilated inferior vena cava in advanced decompensated heart failure. Int J Cardiovasc Imaging. 2014;30:1289–1295.
Jobs A, Brünjes K, Katalinic A, et al. Inferior vena cava diameter in acute decompensated heart failure as predictor of all-cause mortality. Heart Vessels. 2017;32:856–864.
Pérez-Herrero S, Lorenzo-Villalba N, Urbano E, et al. Prognostic significance of lung and cava vein ultrasound in elderly patients admitted for acute heart failure: PROFUND-IC registry analysis. J Clin Med. 2022;11:4591.
Marcelli E, Cercenelli L, Bortolani B, et al. A novel non-invasive device for the assessment of central venous pressure in hospital, office and home. Med Devices (Auckl). 2021;14:141–154.
Jeong SH, Jung DC, Kim SH, et al. Renal venous Doppler ultrasonography in normal subjects and patients with diabetic nephropathy: value of venous impedance index measurements. J Clin Ultrasound. 2011;39:512–518.
Grande D, Terlizzese P, Iacoviello M. Role of imaging in the evaluation of renal dysfunction in heart failure patients. World J Nephrol. 2017;6:123–131.
Iida N, Seo Y, Sai S, et al. Clinical implications of intrarenal hemodynamic evaluation by Doppler ultrasonography in heart failure. JACC Heart Fail. 2016;4:674–682.
Puzzovivo A, Monitillo F, Guida P, et al. Renal venous pattern: a new parameter for predicting prognosis in heart failure outpatients. J Cardiovasc Dev Dis. 2018;5:52.
Yamamoto M, Seo Y, Iida N, et al. Prognostic impact of changes in intrarenal venous flow pattern in patients with heart failure. J Card Fail. 2021;27:20–28.
Tang WH, Kitai T. Intrarenal venous flow: a window into the congestive kidney failure phenotype of heart failure? JACC Heart Fail. 2016;4:683–686.
Seo Y, Iida N, Yamamoto M, et al. Doppler-derived intrarenal venous flow mirrors right-sided heart hemodynamics in patients with cardiovascular disease. Circ J. 2020;84:1552–1559.
Husain-Syed F, Birk HW, Ronco C, et al. Doppler-derived renal venous stasis index in the prognosis of right heart failure. J Am Heart Assoc. 2019;8:e013584.
Deschamps J, Denault A, Galarza L, et al. Venous Doppler to assess congestion: a comprehensive review of current evidence and nomenclature. Ultrasound Med Biol. 2023;49:3–17.
Ohara H, Yoshihisa A, Horikoshi Y, et al. Renal venous stasis index reflects renal congestion and predicts adverse outcomes in patients with heart failure. Front Cardiovasc Med. 2022;9:772466.
Trpkov C, Grant ADM, Fine NM. Intrarenal Doppler ultrasound renal venous stasis index correlates with acute cardiorenal syndrome in patients with acute decompensated heart failure. CJC Open. 2021;3:1444–1452.
Boddi M, Natucci F, Ciani E. The internist and the renal resistive index: truths and doubts. Intern Emerg Med. 2015;10:893–905.
Murphy ME, Tublin ME. Understanding the Doppler RI: impact of renal arterial distensibility on the RI in a hydronephrotic ex vivo rabbit kidney model. J Ultrasound Med. 2000;19:303–314.
Hanamura K, Tojo A, Kinugasa S, et al. The resistive index is a marker of renal function, pathology, prognosis, and responsiveness to steroid therapy in chronic kidney disease patients. Int J Nephrol. 2012;2012:139565.
Ciccone MM, Iacoviello M, Gesualdo L, et al. The renal arterial resistance index: a marker of renal function with an independent and incremental role in predicting heart failure progression. Eur J Heart Fail. 2014;16:210–216.
Caraba A, Iurciuc S, Munteanu A, et al. Hyponatremia and renal venous congestion in heart failure patients. Dis Markers. 2021;2021:6499346.
Citarelli G, Monitillo F, Antoncecchi V, , eds. A high renal arterial resistance index is associated to one year worsening of renal function in heart failure outpatients. In: European Journal of Heart Failure. Wiley-Blackwell; 2014.
Citarelli G, Monitillo F, Leone M, , eds. The presence of an altered renal arterial resistance index is independently associated with the increase of loop diuretic diuretic dose in heart failure outpatients. In: European Journal Of Heart Failure. Wiley-Blackwell; 2014.
Yoshihisa A, Watanabe K, Sato Y, et al. Intrarenal Doppler ultrasonography reflects hemodynamics and predicts prognosis in patients with heart failure. Sci Rep. 2020;10:22257.
Komuro K, Shimazu K, Koizumi T, et al. Demonstration of improved renal congestion after heart failure treatment on renal perfusion imaging with contrast-enhanced ultrasonography. Circ Rep. 2019;1:593–600.
Komuro K, Seo Y, Yamamoto M, et al. Assessment of renal perfusion impairment in a rat model of acute renal congestion using contrast-enhanced ultrasonography. Heart Vessels. 2018;33:434–440.
Taniguchi T, Ohtani T, Kioka H, et al. Liver stiffness reflecting right-sided filling pressure can predict adverse outcomes in patients with heart failure. JACC Cardiovasc Imaging. 2019;12:955–964.
Beaubien-Souligny W, Benkreira A, Robillard P, et al. Alterations in portal vein flow and intrarenal venous flow are associated with acute kidney injury after cardiac surgery: a prospective observational cohort study. J Am Heart Assoc. 2018;7:e009961.
Beaubien-Souligny W, Rola P, Haycock K, et al. Quantifying systemic congestion with point-of-care ultrasound: development of the venous excess ultrasound grading system. Ultrasound J. 2020;12:16.
Bhardwaj V, Vikneswaran G, Rola P, et al. Combination of inferior vena cava diameter, hepatic venous flow, and portal vein pulsatility index: venous excess ultrasound score (VEXUS Score) in predicting acute kidney injury in patients with cardiorenal syndrome: a prospective cohort study. Indian J Crit Care Med. 2020;24:783–789.
Zhang Y, Li Y, Cheng G. Effect of low-dose diuretics on the level of serum cystatin C and prognosis in patients with asymptomatic chronic heart failure. Exp Ther Med. 2015;10:2345–2350.
Ahmad T, Jackson K, Rao VS, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018;137:2016–2028.
Damman K, Ng Kam Chuen MJ, MacFadyen RJ, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol. 2011;57:2233–2241.
Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16:281–288.
Chow SL, O’Barr SA, Peng J, et al. Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. Circ Heart Fail. 2011;4:450–455.
Grodin JL, Perez AL, Wu Y, et al. Circulating kidney injury molecule-1 levels in acute heart failure: insights from the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). JACC Heart Fail. 2015;3:777–785.
Tamaki S, Yamada T, Watanabe T, et al. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study. Circ Heart Fail. 2021;14:e007048.
Metra M, Cotter G, Davison BA, et al.; RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196–206.
Rao VS, Ahmad T, Brisco-Bacik MA, et al. Renal effects of intensive volume removal in heart failure patients with preexisting worsening renal function. Circ Heart Fail. 2019;12:e005552.
Vaduganathan M, Marti CN, Georgiopoulou VV, et al. Classification of patients hospitalized for heart failure. Heart Fail Clin. 2013;9:277–283, v.
Domanski M, Norman J, Pitt B, et al.; Studies of Left Ventricular Dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–708.
Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail. 2008;10:176–187.
Núñez J, Núñez E, Miñana G, et al. Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail. 2012;14:974–984.
Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev. 2007;12:149–156.
Heringlake M, Wernerus M, Grünefeld J, et al. The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting. Crit Care. 2007;11:R51.
Zima E, Farmakis D, Pollesello P, et al. Differential effects of inotropes and inodilators on renal function in acute cardiac care. Eur Heart J Suppl. 2020;22(Suppl D):D12–D19.
Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001;276:9337–9343.
Mebazaa A, Tolppanen H, Mueller C, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med. 2016;42:147–163.
Tarvasmäki T, Lassus J, Varpula M, et al.; CardShock study investigators. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016;20:208. Published 2016 Jul 4.
Hollenberg SM. Vasodilators in acute heart failure. Heart Fail Rev. 2007;12:143–147.
Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [published correction appears in Circulation. 2005 May 3;111(17):2274]. Circulation. 2005;111:1487–1491.
Riter HG, Redfield MM, Burnett JC, et al. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006;47:2334–2335.
Ng TM, Ackerbauer KA, Hyderi AF, et al. Comparative effects of nesiritide and nitroglycerin on renal function, and incidence of renal injury by traditional and RIFLE criteria in acute heart failure. J Cardiovasc Pharmacol Ther. 2012;17:79–85.
Young JB, Cheng M, Mills RM. Hemodynamics, diuretics, and nesiritide: a retrospective VMAC analysis. Clin Cardiol. 2009;32:530–536.
Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752–772.
Gilbert RE. SGLT2 inhibitors: β blockers for the kidney? Lancet Diabetes Endocrinol. 2016;4:814.
Biegus J, Voors AA, Collins SP, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023;44:41–50.
Dekkers CCJ, Petrykiv S, Laverman GD, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20:1988–1993.
Sen T, Li J, Neuen BL, et al. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia. 2021;64:2147–2158.
Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7:75–82.
Conrad KP, Shroff SG. Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep. 2011;13:409–420.
Teerlink JR, Cotter G, Davison BA, et al.; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.